This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.
Here's How Much You'd Have If You Invested $1000 in Edwards Lifesciences a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Strong adoption of the MITRIS RESILIA valve and increased demand for the HemoSphere monitoring platform will likely drive Edwards Lifesciences' (EW) Q4 revenues.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.
Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs
by Zacks Equity Research
Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.
Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.
Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
Edwards Lifesciences (EW) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.61% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intuitive Surgical, Inc. (ISRG) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 8.18% and 2.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.
Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.
Edward Lifesciences (EW) Gains From New Products Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.
OCPNY or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision
by Zacks Equity Research
Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.
Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up
by Zacks Equity Research
Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.
Edwards Lifesciences (EW) Matches Q2 Earnings Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $97.45, marking a -1.99% move from the previous day.
Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $98.43, moving +0.46% from the previous trading session.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Edwards Lifesciences (EW) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $96.03, marking a +1.37% move from the previous day.